Beijing Wantai Bio-pharm

Beijing Wantai is a prominent Chinese biopharmaceutical company specializing in the development, production, and sale of infectious disease diagnostics and vaccines. The company achieved global recognition by launching Hecolin, the world's first Hepatitis E vaccine, and Cecolin, the first Chinese-developed HPV vaccine for cervical cancer prevention. Wantai maintains a dominant position in the Chinese IVD market, offering a wide range of immunoassay and molecular diagnostic tests for blood screening and clinical diagnosis. Through its proprietary E. coli-based recombinant protein platform, the company continues to innovate in the vaccine space, with a high-valent HPV vaccine in late-stage clinical trials and collaborations with global partners like GSK.